Engineered and chimeric nucleases

By constructing an engineered nuclease system, the limitations of the CRISPR/Cas system in gene editing, such as its lack of flexibility and specificity, have been addressed, enabling efficient modification and precise editing of target nucleic acid sequences.

CN122161927APending Publication Date: 2026-06-05METAGENOMICS THERAPEUTICS CO
View PDF 8 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
METAGENOMICS THERAPEUTICS CO
Filing Date
2024-09-13
Publication Date
2026-06-05

AI Technical Summary

Technical Problem

Existing CRISPR/Cas systems suffer from insufficient flexibility and specificity in gene editing applications, making it difficult to effectively modify specific target nucleic acid sequences.

Method used

An engineered nuclease system was developed, comprising an engineered endonuclease and a guide polynucleotide. By constructing a spacer sequence that hybridizes the complex with the target nucleic acid sequence, efficient modification of the target nucleic acid can be achieved.

Benefits of technology

It enables efficient modification of target nucleic acid sequences, including binding, cleavage, or cutting, especially precise editing of specific genes such as albumin, HAO1, AAVS1, and TRAC in mammalian cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122161927A_ABST
    Figure CN122161927A_ABST
Patent Text Reader

Abstract

Disclosed herein are engineered nucleases and nuclease systems, including chimeric nucleases and chimeric nuclease systems. The engineered and chimeric nucleases disclosed herein comprise nucleic acid-guided nucleases. Also disclosed herein are methods of producing engineered nucleases and methods of using the engineered nucleases.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Nucleic acid vaccines

    US10709779B2

  • Regulation of endogenous gene expression in cells using zinc finger proteins

    US20030087817A1

  • N[ omega ,( omega -1)-dialkyloxy]- and N-[ omega ,( omega -1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor

    US4897355A

  • N-( omega ,( omega -1)-dialkyloxy)- and N-( omega ,( omega -1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor

    US4946787A

  • N- omega ,( omega -1)-dialkyloxy)- and N-( omega ,( omega -1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor

    US5049386A